63rd ASH Annual Meeting and Exposition.

Abstract

Addition of the anti-CD38 monoclonal antibody isatuximab to lenalidomide–bortezomib–dexamethasone (RVd) could be a new standard of care for patients with newly diagnosed multiple myeloma, according to results from the GMMG HD7 trial, presented by Hartmut Goldschmidt (University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany). In this phase 3 trial, patients with newly diagnosed, transplantation-eligible multiple myeloma were randomly assigned to RVd (n=329) or RVd plus intravenous isatuximab (n=331) and assessed for minimal residual disease negativity after induction.